Literature DB >> 11097112

New polymorphisms in the human poly(ADP-ribose) polymerase-1 coding sequence: lack of association with longevity or with increased cellular poly(ADP-ribosyl)ation capacity.

F Cottet1, H Blanché, P Verasdonck, I Le Gall, F Schächter, A Bürkle, M L Muiras.   

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) encoded by the PARP-1 gene, is a ubiquitous and abundant DNA-binding protein involved in the cellular response to various genotoxic agents. In a previous study we showed that maximal oligonucleotide-stimulated poly(ADP-ribosyl)ation was significantly higher in permeabilised lymphoblastoid cell lines from a French population of centenarians compared with controls aged 20-70 years, supporting the notion that longevity is associated with a genetically determined, high poly(ADP-ribosyl)ation capacity. Here, we describe four new genetic polymorphisms, three of which represent silent nucleotide variants (C402T, T1011C, G1215A), and one of which leads to a valine762-to-alanine exchange (T2444C). We undertook an association study between two of these polymorphisms and human longevity or poly(ADP-ribosyl)ation capacity in permeabilised lymphoblastoid cells. By analysing 648 DNA samples from a French population (324 centenarians and 324 controls) by fluorescent-allele-specific PCR, we showed the absence of any significant enrichment of any of the genotypes in the study of centenarians versus controls. Furthermore, we studied genotype distributions from individuals who had previously been tested for poly(ADP-ribosyl)ation capacity. None of the genotype combinations at any polymorphic site studied could be related to a high or low level of poly(ADP-ribosyl)ation capacity. Together, these results strongly suggest that the longevity-related differences in the poly(ADP-ribosyl)ation capacity of human lymphoblastoid cell lines cannot be explained by genetic polymorphisms in the PARP-1 coding sequence and that other mechanisms have to be considered as potential regulators of specific poly(ADP-ribosyl)ation capacity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11097112     DOI: 10.1007/s001090000132

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  24 in total

1.  Influence of polymorphisms at loci encoding DNA repair proteins on cancer susceptibility and G2 chromosomal radiosensitivity.

Authors:  Craig S Wilding; Gillian B Curwen; E Janet Tawn; Xiaohua Sheng; Jeanette F Winther; Ranajit Chakraborty; John D Boice
Journal:  Environ Mol Mutagen       Date:  2007-01       Impact factor: 3.216

Review 2.  Genetic epidemiology in aging research.

Authors:  M Daniele Fallin; Amy Matteini
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-01-23       Impact factor: 6.053

3.  PARP-1 and PARP-2: New players in tumour development.

Authors:  José Yelamos; Jordi Farres; Laura Llacuna; Coral Ampurdanes; Juan Martin-Caballero
Journal:  Am J Cancer Res       Date:  2011-01-08       Impact factor: 6.166

4.  Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.

Authors:  Lisa Rank; Sebastian Veith; Eva C Gwosch; Janine Demgenski; Magdalena Ganz; Marjolijn C Jongmans; Christopher Vogel; Arthur Fischbach; Stefanie Buerger; Jan M F Fischer; Tabea Zubel; Anna Stier; Christina Renner; Michael Schmalz; Sascha Beneke; Marcus Groettrup; Roland P Kuiper; Alexander Bürkle; Elisa Ferrando-May; Aswin Mangerich
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971

5.  Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines.

Authors:  T Zaremba; P Ketzer; M Cole; S Coulthard; E R Plummer; N J Curtin
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

6.  Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes.

Authors:  Matteo Citarelli; Sachin Teotia; Rebecca S Lamb
Journal:  BMC Evol Biol       Date:  2010-10-13       Impact factor: 3.260

Review 7.  Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Authors:  Frédérique Mégnin-Chanet; Marc A Bollet; Janet Hall
Journal:  Cell Mol Life Sci       Date:  2010-08-20       Impact factor: 9.261

8.  Racial and tissue-specific cancer risk associated with PARP1 (ADPRT) Val762Ala polymorphism: a meta-analysis.

Authors:  Noel Pabalan; Ofelia Francisco-Pabalan; Hamdi Jarjanazi; Hong Li; Lillian Sung; Hilmi Ozcelik
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

9.  The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients.

Authors:  Ilhan Onaran; Gülçin Tezcan; Levent Ozgönenel; Esra Cetin; Alper Tunga Ozdemir; Gönül Kanigür-Sultuybek
Journal:  Rheumatol Int       Date:  2008-11-22       Impact factor: 2.631

10.  Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.

Authors:  Lili Zhai; Shuai Li; Huilan Li; Yi Zheng; Ronggang Lang; Yu Fan; Feng Gu; Xiaojing Guo; Xinmin Zhang; Li Fu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.